

Jonathan L Silberstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11843258/publications.pdf>

Version: 2024-02-01

62
papers

1,373
citations

471509

17
h-index

330143

37
g-index

62
all docs

62
docs citations

62
times ranked

2292
citing authors

#	ARTICLE	IF	CITATIONS
1	Urine <i>TMPRSS2:ERG</i> Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. <i>Science Translational Medicine</i> , 2011, 3, 94ra72.	12.4	313
2	Physical Models of Renal Malignancies Using Standard Cross-sectional Imaging and 3-Dimensional Printers: A Pilot Study. <i>Urology</i> , 2014, 84, 268-273.	1.0	175
3	Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. <i>BJU International</i> , 2010, 106, 1270-1276.	2.5	86
4	Individualized Physical 3-dimensional Kidney Tumor Models Constructed From 3-dimensional Printers Result in Improved Trainee Anatomic Understanding. <i>Urology</i> , 2015, 85, 1257-1262.	1.0	79
5	3D-printed soft-tissue physical models of renal malignancies for individualized surgical simulation: a feasibility study. <i>Journal of Robotic Surgery</i> , 2018, 12, 27-33.	1.8	76
6	Reverse stage shift at a tertiary care center. <i>Cancer</i> , 2011, 117, 4855-4860.	4.1	62
7	Trends in Partial and Radical Nephrectomy: An Analysis of Case Logs from Certifying Urologists. <i>Journal of Urology</i> , 2013, 190, 464-469.	0.4	62
8	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.4	49
9	Pelvic Lymph Node Dissection for Patients with Elevated Risk of Lymph Node Invasion During Radical Prostatectomy: Comparison of Open, Laparoscopic and Robot-Assisted Procedures. <i>Journal of Endourology</i> , 2012, 26, 748-753.	2.1	48
10	Renal Function and Oncologic Outcomes of Parenchymal Sparing Ureteral Resection Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 187, 429-434.	0.4	41
11	A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. <i>BJU International</i> , 2013, 111, 206-212.	2.5	41
12	Evidence-based Principles of Bladder Cancer and Diet. <i>Urology</i> , 2010, 75, 340-346.	1.0	37
13	Significance and management of positive surgical margins at the time of radical prostatectomy. <i>Indian Journal of Urology</i> , 2014, 30, 423.	0.6	36
14	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. <i>Oncogene</i> , 2019, 38, 7060-7072.	5.9	31
15	Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). <i>BJU International</i> , 2012, 110, 1276-1282.	2.5	30
16	Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. <i>Urology</i> , 2019, 128, 62-65.	1.0	24
17	Clinical Use of PCA3 and <i>TMPRSS2:ERG</i> Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. <i>Journal of Urology</i> , 2016, 196, 1053-1060.	0.4	19
18	Electroencephalographic Monitoring of Brain Wave Activity During Laparoscopic Surgical Simulation to Measure Surgeon Concentration and Stress: Can the Student Become the Master?. <i>Journal of Endourology</i> , 2015, 29, 1329-1333.	2.1	18

#	ARTICLE	IF	CITATIONS
19	Active Surveillance of Prostate Cancer in African American Men. <i>Urology</i> , 2014, 84, 1255-1262.	1.0	17
20	Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. <i>BJU International</i> , 2015, 116, 50-56.	2.5	16
21	Identification of microRNA signature and potential pathway targets in prostate cancer. <i>Experimental Biology and Medicine</i> , 2017, 242, 536-546.	2.4	15
22	Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 380-388.	1.9	15
23	Accelerometer Measurement of Head Movement During Laparoscopic Surgery as a Tool to Evaluate Skill Development of Surgeons. <i>Journal of Surgical Education</i> , 2016, 73, 589-594.	2.5	13
24	Physical Model of Clear-Cell Renal Carcinoma With Inferior Vena Cava Extension Created From a 3-Dimensional Printer to Aid in Surgical Resection: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e867-e869.	1.9	13
25	Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model. <i>BJU International</i> , 2013, 112, 517-525.	2.5	11
26	Rethinking active surveillance for prostate cancer in African American men. <i>Translational Andrology and Urology</i> , 2018, 7, S397-S410.	1.4	10
27	Prospective Observational Study of a Racially Diverse Group of Men on Active Surveillance for Prostate Cancer. <i>Urology</i> , 2021, 148, 203-210.	1.0	8
28	Robotic vs. open surgical management of ureteroenteric anastomotic strictures: technical modifications to enhance success. <i>Journal of Robotic Surgery</i> , 2020, 14, 615-619.	1.8	7
29	Racial Disparities in Histology and Short-Term Renal Functional Outcomes Following Robotic Nephron-Sparing Surgery. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 203-206.	1.9	4
30	Hematologic parameters are not predictors of upgrading or treatment in a racially diverse prospective study of men with prostate cancer on active surveillance. <i>Aging Male</i> , 2020, 23, 1400-1408.	1.9	4
31	Reply. <i>Urology</i> , 2014, 84, 273.	1.0	2
32	Racial variation in prostate needle biopsy templates directed anterior to the peripheral zone. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 336.e1-336.e6.	1.6	2
33	Racial Variation in the Outcome of Subsequent Prostate Biopsies in Men With an Initial Diagnosis of Atypical Small Acinar Proliferation. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e995-e999.	1.9	2
34	Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer. <i>European Urology</i> , 2013, 63, 1130-1131.	1.9	1
35	Testosterone and the Prostate. <i>Sexual Medicine Reviews</i> , 2014, 2, 112-120.	2.9	1
36	Does muscle invasive bladder cancer following pelvic radiotherapy portend worse prognosis? A seer-based study. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100177.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Characterization of abiraterone responses in African American castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 203-203.	1.6	1
38	Clinical performance of PCA3 and TMPRSS2:ERG urinary biomarkers for African American men undergoing prostate biopsy.. Journal of Clinical Oncology, 2015, 33, 91-91.	1.6	1
39	Pelvic Lymph Node Dissection for Prostate Cancer. , 2014, , 57-74.		1
40	Early assessment of PSA response in patients with mCRPC treated with enzalutamide and abiraterone.. Journal of Clinical Oncology, 2017, 35, e574-e574.	1.6	1
41	Editorial Comment from Dr Silberstein to Dr Lazard and Dr Silberstein to Dr Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. International Journal of Urology, 2013, 20, 411-411.	1.0	0
42	Reply. Urology, 2014, 84, 1262.	1.0	0
43	Outcomes of Retroperitoneal Lymph Node Dissection for the Most Challenging Cases. Journal of Urology, 2014, 192, 1320-1321.	0.4	0
44	Editorial Comment from Dr Silberstein to Dr 3-dimensional printing in urological surgery: What are the possibilities?. International Journal of Urology, 2015, 22, 424-425.	1.0	0
45	Reply. Urology, 2015, 85, 1262.	1.0	0
46	Pinpointing uncharacterized prostate cancer in active surveillance patients through mpMRI biopsy.. Journal of Clinical Oncology, 2021, 39, 210-210.	1.6	0
47	Long-term oncologic outcomes of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer.. Journal of Clinical Oncology, 2014, 32, 153-153.	1.6	0
48	Incidence of abiraterone acetate withdrawal response measured by PSA declines.. Journal of Clinical Oncology, 2015, 33, 280-280.	1.6	0
49	Characterization of therapies and timelines for men with prostate cancer-specific mortality.. Journal of Clinical Oncology, 2015, 33, 239-239.	1.6	0
50	Racial variation in positive prostate needle biopsy templates, which include the transition zone.. Journal of Clinical Oncology, 2015, 33, 125-125.	1.6	0
51	Race, inflammation, and prostate cancer: A comparison of African Americans and Caucasians.. Journal of Clinical Oncology, 2016, 34, 246-246.	1.6	0
52	Racial variation in the outcome of subsequent prostate biopsies in men with an initial diagnosis of atypical small acinar proliferation (ASAP).. Journal of Clinical Oncology, 2016, 34, 141-141.	1.6	0
53	Evaluating abiraterone responses in African Americans with metastatic CRPC.. Journal of Clinical Oncology, 2016, 34, 244-244.	1.6	0
54	Utility of PCA3 and TMPRSS2:ERG urinary biomarkers in African American men undergoing prostate biopsy.. Journal of Clinical Oncology, 2016, 34, 126-126.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Pathologic upgrading on confirmatory biopsy in a racially diverse group of men on active surveillance for prostate cancer.. Journal of Clinical Oncology, 2016, 34, 142-142.	1.6	0
56	Racial variations in upgraded gleason scores of active surveillance candidates.. Journal of Clinical Oncology, 2017, 35, e548-e548.	1.6	0
57	Utility of PCA3 and TMPRSS2: ERG urinary biomarkers to predict pathologic outcomes in African American men undergoing radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, e547-e547.	1.6	0
58	Outcomes of men who underwent treatment for prostate cancer from a prospective follow up of a racially diverse, multi-institutional active surveillance cohort.. Journal of Clinical Oncology, 2017, 35, e536-e536.	1.6	0
59	Treatment sequencing of abiraterone and enzalutamide in patients with mCRPC.. Journal of Clinical Oncology, 2017, 35, 233-233.	1.6	0
60	Racial variation in the reliability of prostate cancer indicators in men undergoing subsequent prostate biopsy.. Journal of Clinical Oncology, 2017, 35, 115-115.	1.6	0
61	Baseline differences in characteristics of a racially diverse group of men electing active surveillance.. Journal of Clinical Oncology, 2017, 35, 103-103.	1.6	0
62	A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).. Journal of Clinical Oncology, 2017, 35, TPS5097-TPS5097.	1.6	0